About Retrotope
Retrotope is a company based in Los Altos (United States) founded in 2006 by Mikhail S Shchepinov and Charles Cantor. Retrotope has raised $58.58 million across 7 funding rounds from investors including MP Advisors, Timur Artemev and Morningside China. Retrotope offers products and services including RT001 and RT011. Retrotope operates in a competitive market with competitors including Harmony Biosciences, QurAlis, Passage Bio, Evox Therapeutics and Remegen, among others.
- Headquarter Los Altos, United States
- Founders Mikhail S Shchepinov, Charles Cantor
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Retrotope Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$58.58 M (USD)
in 7 rounds
-
Latest Funding Round
$13.3 M (USD), Series D
Jan 13, 2021
-
Investors
MP Advisors
& 6 more
-
Employee Count
Not available
-
Acquired by
(Jul 29, 2022)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Retrotope
Retrotope offers a comprehensive portfolio of products and services, including RT001 and RT011.
Stabilized Linoleic Acid for treating infantile neuroaxonal dystrophy and other diseases.
Stabilized Docosahexaenoic acid for dry age-related macular degeneration.
People of Retrotope
Unlock access to complete
Unlock access to complete
Funding Insights of Retrotope
Retrotope has successfully raised a total of $58.58M across 7 strategic funding rounds. The most recent funding activity was a Series D round of $13.3 million completed in January 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Retrotope
Retrotope has secured backing from 7 investors, including angel, institutional, and venture fund investors. Prominent investors backing the company include MP Advisors, Timur Artemev and Morningside China.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Life sciences startups are funded by a non-profit angel network.
|
Locked | Locked | Locked | |
|
Early-stage companies are supported through angel investment funding.
|
Locked | Locked | Locked | |
|
Early-stage venture capital investments are made in medical startups.
|
Locked | Locked | Locked |
Investor details for Retrotope
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Retrotope
Investment portfolio details for Retrotope
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Retrotope
Detailed financials for Retrotope
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Retrotope Comparisons
Peer comparison for Retrotope
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Retrotope
Retrotope operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Harmony Biosciences, QurAlis, Passage Bio, Evox Therapeutics and Remegen, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of therapeutics for rare neurological diseases
|
|
| Locked | Locked | Locked |
Drugs and CSF devices are developed for ALS treatment.
|
|
| Locked | Locked | Locked |
Gene therapies for CNS rare diseases are developed.
|
|
| Locked | Locked | Locked |
Exosome-based gene therapies for neurological diseases are developed.
|
|
| Locked | Locked | Locked |
Therapies for cancer, autoimmune, and eye diseases are developed.
|
|
| Locked | Locked | Locked |
Psychedelic-based therapies for brain health disorders are developed.
|
Detailed competitors of Retrotope
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Retrotope
Complete news archive for Retrotope
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Retrotope
Retrotope was founded in 2006 and raised its 1st funding round 10 years after it was founded.
Retrotope is headquartered in Los Altos, United States. It is registered at Los Altos, California, United States.
Retrotope is a funded company, having raised a total of $58.58M across 7 funding rounds to date.
Founded in 2006 and headquartered in Los Altos, United States, therapeutics are developed by Retrotope to address neurodegenerative and ophthalmological diseases. A proprietary drug discovery platform is utilized to produce disease-modifying drugs that target oxidative stress and cellular degeneration from lipid peroxidation. Lead candidates include RT001 for infantile neuroaxonal dystrophy, Friedreichs ataxia, and amyotrophic lateral sclerosis, alongside RT011 for dry age-related macular degeneration and geographic atrophy.
Retrotope's top competitors include Harmony Biosciences, QurAlis and MindMed.
Retrotope offers RT001 and RT011.
Retrotope has 7 investors. Key investors include MP Advisors, Timur Artemev, Morningside China, Life Science Angels, and North Texas Angel Network.